Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program
Recruiting · NCT04652609 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
PRESIONA
What this trial is about
The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.
Who can take part
Age range
18 Years to 70 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- 18 years or older
- HER2+ breast cancer diagnosis
- On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy)
Exclusion criteria
- Previous diagnosis of cancer
- Pregnant
- Cardiac pathology
- No symptoms or pathology that could be confused with neuropathy or related to diabetes
- No recommendation from oncologist for therapeutic exercise practice
Where it is running
1 location listed.
- University of Granada - Granada, Spain